

Markus Peck-Radosavljevic

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2680614/markus-peck-radosavljevic-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

233
papers

12,146
citations

61
h-index

103
g-index

258
ext. papers

14,326
ext. citations

5.6
avg, IF

6.34
L-index

#	Paper	IF	Citations
233	The burden of liver disease in Europe: a review of available epidemiological data. <i>Journal of Hepatology</i> , 2013 , 58, 593-608	13.4	858
232	Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 57-67	27.4	427
231	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2016 , 16, 685-697	25.5	346
230	Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. <i>Cancer Cell</i> , 2010 , 17, 286-97	24.3	335
229	Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. <i>Liver International</i> , 2013 , 33, 1138-47	7.9	300
228	Nonselective beta-blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. <i>Gastroenterology</i> , 2014 , 146, 1680-90.e1	13.3	257
227	The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013 , 57, 2261-73	11.2	230
226	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i> , 2013 , 62, 1634-41	19.2	214
225	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013 , 58, 911-21	13.4	211
224	Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. <i>Gut</i> , 2003 , 52, 879-85	19.2	210
223	Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. <i>Journal of Hepatology</i> , 2006 , 44, 151-7	13.4	191
222	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. <i>Journal of Hepatology</i> , 2016 , 65, 692-699	13.4	190
221	An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. <i>Liver Transplantation</i> , 2007 , 13, 1174-80	4.5	178
220	Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. <i>American Journal of Gastroenterology</i> , 2006 , 101, 2511-9	0.7	165
219	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021 , 592, 450-456	50.4	164
218	Transarterial chemoembolization: modalities, indication, and patient selection. <i>Journal of Hepatology</i> , 2015 , 62, 1187-95	13.4	163
217	EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. <i>Nature Cell Biology</i> , 2014 , 16, 972-7	23.4	162

216	Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. <i>Blood</i> , 2000 , 95, 795-801	2.2	159
215	Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. <i>Radiology</i> , 2012 , 263, 590-9	20.5	154
214	Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?. <i>Journal of Hepatology</i> , 1997 , 27, 127-31	13.4	150
213	Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. <i>Gut</i> , 2016 , 65, 1861-1870 ¹⁴⁶	19.3	146
212	Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. <i>Oncologist</i> , 2009 , 14, 70-6	5.7	144
211	Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2017 , 166, 109-117	8	138
210	Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. <i>European Journal of Radiology</i> , 2012 , 81, 4112-8	4.7	133
209	Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. <i>Hepatology</i> , 2003 , 38, 1043-1050	11.2	132
208	Cancer and liver cirrhosis: implications on prognosis and management. <i>ESMO Open</i> , 2016 , 1, e000042	6	124
207	Thrombocytopenia in liver disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2000 , 14 Suppl D, 60D-66D		122
206	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019 , 71, 1164-1174	13.4	119
205	von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. <i>Hepatology</i> , 2012 , 56, 1439-47	11.2	116
204	Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. <i>Transplantation</i> , 2007 , 83, 425-32	1.8	115
203	Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. <i>Gastroenterology</i> , 2002 , 123, 141-51	13.3	111
202	How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014 , 61, 1287-96	13.4	104
201	Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 8, 212-23	24.2	103
200	Axl activates autocrine transforming growth factor- β signaling in hepatocellular carcinoma. <i>Hepatology</i> , 2015 , 61, 930-41	11.2	97
199	The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. <i>Journal of Hepatology</i> , 2014 , 60, 118-26	13.4	96

198	Thrombocytopenia in chronic liver disease. <i>Liver International</i> , 2017 , 37, 778-793	7.9	96
197	Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. <i>American Journal of Gastroenterology</i> , 2002 , 97, 2880-5	0.7	96
196	Creation of transjugular intrahepatic portosystemic shunts with stent-grafts: initial experiences with a polytetrafluoroethylene-covered nitinol endoprosthesis. <i>Radiology</i> , 2001 , 221, 437-46	20.5	94
195	Review article: systemic treatment of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 598-609	6.1	92
194	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. <i>Liver International</i> , 2015 , 35, 381-90	7.9	90
193	The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. <i>Journal of Hepatology</i> , 2017 , 66, 724-733	13.4	87
192	Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. <i>Journal of Hepatology</i> , 2009 , 51, 865-73	13.4	85
191	Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. <i>Hepatology</i> , 1998 , 28, 1424-9	11.2	84
190	NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. <i>Surgery</i> , 2011 , 149, 311-20	3.6	83
189	Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. <i>American Journal of Pathology</i> , 2010 , 176, 472-81	5.8	83
188	Noninvasive screening for liver fibrosis and portal hypertension by transient elastography--a large single center experience. <i>Wiener Klinische Wochenschrift</i> , 2012 , 124, 395-402	2.3	79
187	Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. <i>Hepatology</i> , 2003 , 38, 1043-50	11.2	79
186	Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013 , 57, 2224-34	11.2	78
185	Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). <i>Wiener Klinische Wochenschrift</i> , 2017 , 129, 135-158	2.3	76
184	Hypersplenism. <i>European Journal of Gastroenterology and Hepatology</i> , 2001 , 13, 317-23	2.2	74
183	DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. <i>Endocrinology</i> , 1999 , 140, 5136-48	4.8	72
182	Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. <i>Journal of Hepatology</i> , 2009 , 51, 47-54	13.4	67
181	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. <i>Hepatology</i> , 2020 , 71, 1023-1036	11.2	67

180	6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2495-503	0.7	65
179	IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV/HCV Coinfection. <i>Antiviral Therapy</i> , 2008 , 13, 969-976	1.6	65
178	The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: a retrospective multicentre study. <i>Digestive and Liver Disease</i> , 2013 , 45, 762-8	3.3	63
177	Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. <i>Gut</i> , 2021 , 70, 204-214	19.2	63
176	Drug therapy for advanced-stage liver cancer. <i>Liver Cancer</i> , 2014 , 3, 125-31	9.1	62
175	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1323-1333	6.1	61
174	Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. <i>International Journal of Cancer</i> , 2001 , 91, 789-796	7.5	61
173	HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 400-9	3.4	59
172	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 391-8	2.2	56
171	Transforming Growth Factor- β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019 , 69, 222-236	11.2	53
170	Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 602-8.e1	6.9	53
169	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. <i>Liver International</i> , 2015 , 35, 2121-8	7.9	52
168	Review article: coagulation disorders in chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26 Suppl 1, 21-8	6.1	52
167	Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. <i>Gut</i> , 2005 , 54, 1014-20	19.2	50
166	KiSS-1 overexpression as an independent prognostic marker in hepatocellular carcinoma: an immunohistochemical study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007 , 450, 143-9	5.1	49
165	123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. <i>Nuclear Medicine and Biology</i> , 1996 , 23, 685-92	2.1	49
164	Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. <i>American Journal of Transplantation</i> , 2007 , 7, 1763-9	8.7	48
163	Mutations of the HFE gene in patients with hepatocellular carcinoma. <i>American Journal of Gastroenterology</i> , 2003 , 98, 442-7	0.7	48

162	Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. <i>CardioVascular and Interventional Radiology</i> , 2005 , 28, 313-8	2.7	47
161	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020 , 72, 198-212	11.2	47
160	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. <i>Radiology</i> , 2015 , 277, 903-12	20.5	46
159	Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. <i>European Journal of Haematology</i> , 2006 , 77, 513-7	3.8	45
158	Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. <i>Annals of Oncology</i> , 2003 , 14, 1274-7	10.3	45
157	Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival?. <i>Transplant International</i> , 2006 , 19, 275-81	3	44
156	Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?. <i>Wiener Klinische Wochenschrift</i> , 2011 , 123, 542-51	2.3	43
155	Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfecting patient. <i>Journal of Clinical Virology</i> , 2010 , 49, 131-3	14.5	43
154	Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. <i>PLoS ONE</i> , 2014 , 9, e110503	3.7	43
153	Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma. <i>Hepatology</i> , 2012 , 55, 1112-21	11.2	42
152	Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. <i>European Radiology</i> , 2012 , 22, 1214-23	8	41
151	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 313-327.e6	6.9	41
150	Advances in the management of HIV/HCV coinfection. <i>Hepatology International</i> , 2016 , 10, 424-35	8.8	40
149	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 4650-4661	12.9	38
148	Physical performance and health-related quality of life in men on a liver transplantation waiting list. <i>Journal of Rehabilitation Medicine</i> , 2001 , 33, 260-5	3.4	38
147	Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfecting patients. <i>Aids</i> , 2013 , 27, 227-32	3.5	37
146	Repeat interventions for maintenance of transjugular intrahepatic portosystemic shunt function in patients with Budd-Chiari syndrome. <i>Journal of Vascular and Interventional Radiology</i> , 2002 , 13, 193-9	2.4	37
145	Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. <i>Liver International</i> , 2015 , 35, 2115-20	7.9	36

144	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). <i>Wiener Klinische Wochenschrift</i> , 2013 , 125, 200-19	2.3	36
143	Effects of TIPS on liver perfusion measured by dynamic CT. <i>American Journal of Roentgenology</i> , 2005 , 184, 505-10	5.4	36
142	Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. <i>Journal of Hepatology</i> , 2011 , 54, 89-97	13.4	35
141	Aerobic capacity, muscle strength and health-related quality of life before and after orthotopic liver transplantation: preliminary data of an Austrian transplantation centre. <i>Journal of Rehabilitation Medicine</i> , 2006 , 38, 322-8	3.4	34
140	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017 , 5, 987-996	5.3	33
139	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1657-65	4	33
138	Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. <i>PLoS ONE</i> , 2012 , 7, e43143	3.7	33
137	ePTFE-covered stent-grafts for revision of obstructed transjugular intrahepatic portosystemic shunt. <i>CardioVascular and Interventional Radiology</i> , 2002 , 25, 365-72	2.7	32
136	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. <i>Aids</i> , 2016 , 30, 1039-47	3.5	32
135	Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20, 437-43	6.1	31
134	In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996 , 23, 1388-99		31
133	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019 , 8, 203-217	9.1	31
132	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. <i>Journal of Hepatology</i> , 2014 , 60, 1135-42	13.4	30
131	Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. <i>Liver International</i> , 2015 , 35, 876-85	7.9	29
130	Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. <i>Antiviral Therapy</i> , 2011 , 16, 815-24	1.6	29
129	Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. <i>Wiener Klinische Wochenschrift</i> , 2017 , 129, 8-15	2.3	28
128	Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. <i>Critical Care Medicine</i> , 2005 , 33, 2028-33	1.4	28
127	PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension. <i>PLoS ONE</i> , 2014 , 9, e108544	3.7	27

126	A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , 2012 , 17, 1327-34	1.6	26
125	Pretransplant screening of sobriety with carbohydrate-deficient transferrin in patients suffering from alcoholic cirrhosis. <i>Transplant International</i> , 2004 , 17, 617-621	3	26
124	Austrian consensus on the definition and treatment of portal hypertension and its complications. <i>Endoscopy</i> , 2005 , 37, 667-73	3.4	26
123	Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). <i>Wiener Klinische Wochenschrift</i> , 2016 , 128, 679-690	2.3	26
122	Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. <i>Liver International</i> , 2014 , 34, 69-77	7.9	25
121	Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012 , 57, 592-9	13.4	25
120	Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 1999 , 11, 151-6	2.2	25
119	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. <i>Scientific Reports</i> , 2018 , 8, 9372	4.9	24
118	Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 242-8	6.9	24
117	Equilibrium of acidifying and alkalinizing metabolic acid-base disorders in cirrhosis. <i>Liver International</i> , 2005 , 25, 505-12	7.9	24
116	Elevated levels of serum carbohydrate deficient transferrin are not specific for alcohol abuse in patients with liver disease. <i>Journal of Hepatology</i> , 1995 , 23, 706-11	13.4	24
115	IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. <i>European Journal of Clinical Investigation</i> , 2012 , 42, 599-606	4.6	23
114	Incidence and mortality trends for biliary tract cancers in Austria. <i>Liver International</i> , 2014 , 34, 1102-8	7.9	23
113	Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2009 , 41, 902-6	3.3	23
112	Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. <i>Blood</i> , 2002 , 99, 4246-7	2.2	23
111	Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. <i>Journal of Visualized Experiments</i> , 2020 ,	1.6	23
110	Neuropilin-2 induced by transforming growth factor- β augments migration of hepatocellular carcinoma cells. <i>BMC Cancer</i> , 2015 , 15, 909	4.8	22
109	Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2013 , 1, 265-75	5.3	22

108	A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. <i>Liver International</i> , 2010 , 30, 574-82	7.9	22
107	EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 172-172	2.2	21
106	ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , 2018 , 38, 1036-1044	7.9	20
105	Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine. <i>Ultrasound in Medicine and Biology</i> , 2015 , 41, 2340-9	3.5	20
104	Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. <i>PLoS ONE</i> , 2015 , 10, e0116768	3.7	20
103	Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease. <i>Antiviral Therapy</i> , 2017 , 22, 225-236	1.6	20
102	Thrombopoietin in Plasmodium falciparum malaria. <i>British Journal of Haematology</i> , 2000 , 109, 534-6	4.5	19
101	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015 , 10, e0143429	3.7	19
100	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience. <i>PLoS ONE</i> , 2018 , 13, e0189414	3.7	18
99	Direct evidence for an increase in thrombopoiesis after liver transplantation. <i>European Journal of Clinical Investigation</i> , 1998 , 28, 755-9	4.6	17
98	Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2008 , 20, 1012-9	2.2	17
97	Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 21, 49-55	6.1	17
96	The impact of thyroid hormones on patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017 , 12, e0181837	3.7	17
95	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2021 ,	13.4	17
94	Prevention of progression from small to large varices: are we there yet? An updated meta-analysis. <i>Gut</i> , 2017 , 66, 1347-1349	19.2	16
93	Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease. <i>Transplant International</i> , 2017 , 30, 243-255	3	16
92	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. <i>Liver International</i> , 2018 , 38, 1427-1436	7.9	16
91	Liver disease in adults with α1-antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , 2018 , 6, 710-718	5.3	16

90	Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. <i>Liver International</i> , 2013 , 33, 561-8	7.9	15
89	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. <i>Digestive and Liver Disease</i> , 2017 , 49, 1360-1367	3.3	15
88	The value of [C]-acetate PET and [F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1732-1741	8.8	15
87	Comparison of (11)C-acetate positron emission tomography and (67)Gallium citrate scintigraphy in patients with hepatocellular carcinoma. <i>Liver International</i> , 2006 , 26, 920-7	7.9	15
86	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study. <i>Medicine (United States)</i> , 2016 , 95, e4061	1.8	15
85	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. <i>Biomedicines</i> , 2021 , 9,	4.8	15
84	Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options. <i>Journal of Molecular Medicine</i> , 2017 , 95, 753-765	5.5	14
83	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. <i>Digestive and Liver Disease</i> , 2019 , 51, 1144-1151	3.3	14
82	Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End-stage Liver Disease score. <i>European Journal of Clinical Investigation</i> , 2009 , 39, 65-71	4.6	14
81	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. <i>Oncotarget</i> , 2018 , 9, 10054-10068	3.3	14
80	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020 , 40, 260-270	7.9	14
79	Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection. <i>European Journal of Clinical Investigation</i> , 2008 , 38, 421-9	4.6	13
78	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 184-190	4	12
77	Austrian Joint EGH-EUR-EHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. <i>Wiener Klinische Wochenschrift</i> , 2012 , 124, 104-103	7.0	12
76	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013 , 27, 2707-14	3.5	12
75	Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2010 , 202, 156-60	7	12
74	Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellular carcinoma after liver transplantation than albumin mRNA in peripheral blood. Liver Transplant Oncology Group. <i>Journal of Hepatology</i> , 1998 , 28, 497-503	13.4	12
73	Development of an avian model for restenosis. <i>Atherosclerosis</i> , 1996 , 119, 17-41	3.1	12

72	Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). <i>Journal of Hepatology</i> , 2016 , 64, 1452-4	13.4	11
71	Effects of Portal Hypertension on Gadoteric Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications. <i>Investigative Radiology</i> , 2017 , 52, 462-469	10.1	11
70	Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection. <i>PLoS ONE</i> , 2013 , 8, e66831	3.7	11
69	Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy. <i>American Journal of Gastroenterology</i> , 2006 , 101, 2275-82	6.7	11
68	Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. <i>Wiener Klinische Wochenschrift</i> , 2018 , 130, 105-114	2.3	11
67	A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia. <i>Hematology</i> , 2019 , 24, 679-719	2.2	10
66	Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. <i>AIDS Patient Care and STDs</i> , 2014 , 28, 221-7	5.8	10
65	Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. <i>Transplant International</i> , 2015 , 28, 1011-24	3	10
64	von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4. <i>Antiviral Therapy</i> , 2010 , 15, 831-9	1.6	10
63	Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. <i>Liver International</i> , 2015 , 35, 1393-402	7.9	9
62	Managing complications in cirrhotic patients. <i>United European Gastroenterology Journal</i> , 2015 , 3, 80-94	5.3	9
61	Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response. <i>Gastroenterology</i> , 2018 , 154, 1550-1551	13.3	9
60	Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging. <i>Academic Radiology</i> , 2017 , 24, 1491-1500	4.3	9
59	Response-guided boceprevir-based triple therapy in HIV/HCV-coinfecting patients: the HIVCOBOC-RGT study. <i>Journal of Infectious Diseases</i> , 2015 , 211, 729-35	7	9
58	Epidemiological trends of hepatocellular carcinoma in Austria. <i>Digestive Diseases</i> , 2014 , 32, 664-9	3.2	9
57	Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , 2020 , 40, 393-404	7.9	9
56	Platelet Dysfunction: Status of Thrombopoietin in Thrombocytopenia Associated with Chronic Liver Failure. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 455-61	5.3	8
55	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019 , 7, 850-858	5.3	8

54	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. <i>Wiener Klinische Wochenschrift</i> , 2017 , 129, 517-526	2.3	8
53	Hepatocellular carcinoma: the place of new medical therapies. <i>Therapeutic Advances in Gastroenterology</i> , 2010 , 3, 259-67	4.7	8
52	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. <i>Hepatology Research</i> , 2019 , 49, 201-211	5.1	8
51	Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. <i>Wiener Klinische Wochenschrift</i> , 2011 , 123, 61-4	2.3	7
50	Transjugular intrahepatic portosystemic shunt in Vienna--a decade later. <i>Wiener Klinische Wochenschrift</i> , 2004 , 116, 608-13	2.3	7
49	Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 238-238	2.2	7
48	Transjugular intrahepatic portosystemic shunt and cardiac arrhythmias. <i>Journal of Clinical Gastroenterology</i> , 1998 , 26, 39-43	3	7
47	The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria. <i>Liver International</i> , 2021 , 41, 1058-1069	7.9	7
46	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 1008-1015	2.4	6
45	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoteric Acid-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , 2018 , 2018, 8489709	3.2	6
44	Back to basics: staging and prognosis in HCC for medical oncologist. <i>Journal of Hepatology</i> , 2012 , 56, 488-9	13.4	6
43	Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C. <i>Thrombosis and Haemostasis</i> , 2006 , 95, 260-6	7	6
42	The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. <i>Liver International</i> , 2016 , 36, 1649-1656	7.9	6
41	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , 2018 , 44, 2578-2586	3.5	6
40	Endoscopic versus surgical management of biliary complications - Outcome analysis after 1188 orthotopic liver transplantations. <i>Digestive and Liver Disease</i> , 2016 , 48, 1323-1329	3.3	5
39	Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy. <i>Antiviral Therapy</i> , 2014 , 19, 407-14	1.6	5
38	Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. <i>Oncotarget</i> , 2017 , 8, 57109-57120	3.3	4
37	Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009 , 28, 142	12.8	4

36	Postural control in patients with liver cirrhosis: a posturographic study. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 915-22	2.2	4
35	Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient. <i>Liver International</i> , 2020 , 40, 988-989	7.9	4
34	Systemic therapy of advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2021 , 17, 1237-1251	3.6	4
33	Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. <i>United European Gastroenterology Journal</i> , 2021 ,	5.3	4
32	MR-guided percutaneous ethanol ablation of hepatocellular carcinomas before liver transplantation. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2007 , 16, 230-40	2.1	3
31	Percutaneous ethanol instillation therapy for hepatocellular carcinoma - a randomized controlled trial. <i>Wiener Klinische Wochenschrift</i> , 2008 , 120, 608-18	2.3	3
30	MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1080-1089	6.1	3
29	Reply to the letters to the editor regarding the sequential ART-score. <i>Journal of Hepatology</i> , 2014 , 61, 177-8	13.4	2
28	Child-PUGH- vs. meld-score to predict survival after tips: the Vienna-experience with 349 patients over 10 years. <i>Journal of Hepatology</i> , 2002 , 36, 16	13.4	2
27	Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. <i>Wiener Klinische Wochenschrift</i> , 2021 , 133, 421-431	2.3	2
26	Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. <i>Wiener Klinische Wochenschrift</i> , 2016 , 128, 414-20	2.3	1
25	Reply: To PMID 24631577. <i>Gastroenterology</i> , 2014 , 147, 942	13.3	1
24	Portal hypertension--old problem, new therapeutic solutions. <i>Wiener Medizinische Wochenschrift</i> , 2006 , 156, 397-403	2.9	1
23	Digestive health in Europe - lack of concerted action, exposed by COVID-19, starts with lack of uniform data reporting in liver disease. <i>Infectious Diseases</i> , 2020 , 52, 828-829	3.1	1
22	Challenges in hepatitis C elimination despite highly effective antiviral agents in patients with and without intravenous drug use. <i>Wiener Klinische Wochenschrift</i> , 2021 , 133, 641-646	2.3	1
21	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , 2021 , 15, 1160-1173	8.8	1
20	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , 2016 , 48, 1194-9	3.3	1
19	MAFLD, HCC and the dilemma of (changing) terminology in liver diseases.. <i>Gut</i> , 2022 ,	19.2	1

18	Research update for articles published in EJCI in 2008. <i>European Journal of Clinical Investigation</i> , 2010 , 40, 770-789	4.6	o
17	The bleeding risk after endoscopic ultrasound-guided puncture of pancreatic masses. <i>Scandinavian Journal of Gastroenterology</i> , 2021 , 56, 205-210	2.4	o
16	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension.. <i>Advances in Medical Sciences</i> , 2022 , 67, 154-162	2.8	o
15	Reply: To PMID 23316013. <i>Hepatology</i> , 2014 , 59, 2425-6	11.2	
14	Reply: To PMID 22532296. <i>Hepatology</i> , 2013 , 58, 1189-90	11.2	
13	Portale Hypertension. <i>Wiener Klinische Wochenschrift Education</i> , 2013 , 8, 1-13	0.2	
12	Entering a new era in the treatment of hepatitis C. <i>Digestive and Liver Disease</i> , 2014 , 46 Suppl 5, S157	3.3	
11	The "pegylated" story continues--perhaps because both ends (H2a and H2b) are true?. <i>Journal of Hepatology</i> , 2012 , 57, 226-8; author reply 229	13.4	
10	Advances in haematology and oncology 2011: hepatocellular carcinoma (HCC). <i>Memo - Magazine of European Medical Oncology</i> , 2012 , 5, 161-162	0.3	
9	TACE it or leave it: hard choices for intermediate-stage hepatocellular carcinoma patients beyond perfect health. <i>Liver International</i> , 2010 , 30, 3-4	7.9	
8	Das hepatozelluläre Karzinom. <i>Wiener Klinische Wochenschrift Education</i> , 2009 , 4, 33-41	0.2	
7	Portale Hypertension. <i>Wiener Klinische Wochenschrift Education</i> , 2008 , 3, 107-118	0.2	
6	TIPS [Relevant for Therapy of Variceal Bleeding?]. <i>Visceral Medicine</i> , 2005 , 21, 224-229	2.4	
5	Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. <i>European Journal of Haematology</i> , 2006 , 060928002456001-???	3.8	
4	Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4074-4074	2.2	
3	Antiviral Treatments and Residual Risk of Hepatic Decompensation 2016 , 99-104		
2	Comparative outcome of sorafenib treatment in central Europe and Russia.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14681-e14681	2.2	
1	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , 2017 , 16, 375-381	3.1	

